



NEWS RELEASE
FOR IMMEDIATE RELEASE

TSX-Venture: AMF

AMORFIX RECEIVES APPROVAL TO LIST ON THE TORONTO STOCK EXCHANGE

TORONTO, Ontario – July 17, 2007 – Amorfix Life Sciences (TSX-V: AMF), a company focused on diagnostics and treatments for brain wasting diseases today announced that the common shares of the Company have been conditionally approved for listing on the Toronto Stock Exchange (TSX). Amorfix is currently listed on the TSX Venture Exchange.

“The graduation to the TSX reflects the ongoing progress of our overall business plan, setting milestones and working to achieve them in a timely fashion, whether it is related to our corporate objectives or our product development,” said Dr. George Adams, CEO of Amorfix Life Sciences. “As we move towards commercialization of our diagnostic blood screening test for vCJD and advance and expand our therapeutic program, the TSX provides access to a broader base of potential investors and supports our strategic growth objectives.”

Listing is subject to Amorfix fulfilling certain documentary and filing requirements of the TSX. Amorfix will issue a further press release to advise when its common shares will commence trading on the TSX. Upon listing, Amorfix’s common shares will continue to trade under the symbol AMF.

About Amorfix

Amorfix Life Sciences Ltd. (TSX-V:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting brain-wasting diseases including ALS, Alzheimer’s Disease, Parkinson’s Disease and variant Creutzfeldt-Jakob Disease (vCJD). Amorfix’s proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and the ability to identify AMPs and understand their structure and mechanism of folding are the first steps to developing new treatments for these devastating diseases. Amorfix’s lead program is a diagnostic blood screening test for vCJD.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

Dr. George Adams President & Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 482-3813 Fax: (416) 482-3811 george.adams@amorfix.com	James Parsons Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 482-3814 Fax: (416) 482-3811 james.parsons@amorfix.com
---	---